Genta initiates new dose-ranging study of tesetaxel drug

[News]

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

More... (http://www.news-medical.net/news/20100226/Genta-initiates-new-dose-ranging-study-of-tesetaxel-drug.aspx)